---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-003329"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:35:03.643174+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cingulate receives $3M grant from private foundation to accelerate CTx-2103 (buspirone) development

## Summary
- Grant of $3M in three $1M tranches; first payment May 1, 2025, others upon formulation and development milestones.
- Non-dilutive funding; contingent royalty of $500K per quarter after first commercial sale, max cumulative $3.5M.
- CTx-2103 (buspirone) potential first once-daily formulation for anxiety; U.S. market $5.5B, global $11.6B.
- Grant expands pipeline and validates Cingulate's proprietary Precision Timed Release drug delivery platform.

## SEC filing metadata
- accession: 0001641172-25-003329
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000164117225003329/0001641172-25-003329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000164117225003329/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-003329
- JSON: https://secwatch.observer/filing/0001641172-25-003329.json
- Plain text: https://secwatch.observer/filing/0001641172-25-003329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.